Skip to content

Study · Animal study (in vivo) · mouse · 2026

7 results

[Costunolide improves sorafenib-induced cardiomyocyte injury by inhibiting mitophagy].

Niu DD, Wang C, Duan CE

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica1 Jul 2026

PMID42543344 (opens in a new tab)DOI10.19540/j.cnki.cjcmm.20260406.801 (opens in a new tab)PepBankPUB-42543344
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In sorafenib-treated mice, adding AICAR reversed COS-associated changes in cardiac functional indices compared with high-dose COS alone.

    In plain wordsIn mice, adding AICAR reversed changes in cardiac functional indices compared with sorafenib plus high-dose COS.

    Peptide
    AICAR (acadesine)
    Outcome
    MixedCardiac functional indices
    Study

    mousen = 20

    Sorafenib-treated male C57BL/6J mice
    Comparator
    SOR+high-COS
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Upon further addition of rapamycin and AICAR, both cardiac functional indices and protein expression levels displayed trends opposite to those in the SOR+high-COS group(P<0.05).
    2 context sentences
    Summary · context
    Concurrently, male C57BL/6J mice were randomly assigned to six groups(10 per group): ctrl group, SOR group, SOR + low-COS group, SOR + high-COS group, SOR + high-COS + rapamycin group, and SOR + high-COS + AICAR group.
    Summary · context
    Animal experiments exhibited a similar trend: the SOR group showed significant differences in multiple cardiac functional parameters and protein expression levels compared with the ctrl group, which were ameliorated by COS treatment.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In sorafenib-treated mice, adding AICAR reversed COS-associated changes in cardiac protein expression compared with high-dose COS alone.

    In plain wordsIn mice, adding AICAR reversed changes in cardiac protein expression compared with sorafenib plus high-dose COS.

    Peptide
    AICAR (acadesine)
    Outcome
    MixedCardiac protein expression
    Study

    mousen = 20

    Sorafenib-treated male C57BL/6J mice
    Comparator
    SOR+high-COS
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Upon further addition of rapamycin and AICAR, both cardiac functional indices and protein expression levels displayed trends opposite to those in the SOR+high-COS group(P<0.05).
    2 context sentences
    Summary · context
    Concurrently, male C57BL/6J mice were randomly assigned to six groups(10 per group): ctrl group, SOR group, SOR + low-COS group, SOR + high-COS group, SOR + high-COS + rapamycin group, and SOR + high-COS + AICAR group.
    Summary · context
    Animal experiments exhibited a similar trend: the SOR group showed significant differences in multiple cardiac functional parameters and protein expression levels compared with the ctrl group, which were ameliorated by COS treatment.
  3. 03LabIn vitro (cells)Mechanism

    In sorafenib-treated H9c2 cells, adding AICAR to high-dose COS increased LDH leakage compared with high-dose COS alone.

    In plain wordsIn cells, adding AICAR increased LDH leakage compared with sorafenib plus high-dose COS.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseLDH leakage
    Study

    n: not reported in source

    Sorafenib-treated H9c2 cells
    Comparator
    SOR+high-COS
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 24 hoursAs given in this study.

    Source sentences

    Summary
    Further addition of rapamycin and AICAR resulted in changes opposite to those observed in the SOR+high-COS groups(P<0.05).
    3 context sentences
    Summary · context
    H9c2 cells were divided into six groups: control(ctrl) group, SOR group, SOR + low-dose COS(SOR+low-COS) group, SOR + high-dose COS(SOR+high-COS) group, SOR + high-COS + rapamycin group, and SOR + high-COS + adenosine monophosphate-activated protein kinase(AMPK) activator(AICAR) group, with each gro…
    Summary · context
    Compared with the ctrl group, the SOR group exhibited notable changes in multiple indicators, including a significant increase in lactate dehydrogenase(LDH) leakage rate, LC3-related indices, and the expression levels of various autophagy-related proteins, as well as a significant decrease in mitoch…
    Summary · context
    Following COS administration, these indices were significantly reversed in the SOR+low-COS and SOR+high-COS groups(P<0.05).
  4. 04LabIn vitro (cells)Mechanism

    In sorafenib-treated H9c2 cells, adding AICAR to high-dose COS increased LC3-related indices compared with high-dose COS alone.

    In plain wordsIn cells, adding AICAR increased LC3-related indices compared with sorafenib plus high-dose COS.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseLC3-related indices
    Study

    n: not reported in source

    Sorafenib-treated H9c2 cells
    Comparator
    SOR+high-COS
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 24 hoursAs given in this study.

    Source sentences

    Summary
    Further addition of rapamycin and AICAR resulted in changes opposite to those observed in the SOR+high-COS groups(P<0.05).
    3 context sentences
    Summary · context
    H9c2 cells were divided into six groups: control(ctrl) group, SOR group, SOR + low-dose COS(SOR+low-COS) group, SOR + high-dose COS(SOR+high-COS) group, SOR + high-COS + rapamycin group, and SOR + high-COS + adenosine monophosphate-activated protein kinase(AMPK) activator(AICAR) group, with each gro…
    Summary · context
    Compared with the ctrl group, the SOR group exhibited notable changes in multiple indicators, including a significant increase in lactate dehydrogenase(LDH) leakage rate, LC3-related indices, and the expression levels of various autophagy-related proteins, as well as a significant decrease in mitoch…
    Summary · context
    Following COS administration, these indices were significantly reversed in the SOR+low-COS and SOR+high-COS groups(P<0.05).
  5. 05LabIn vitro (cells)Mechanism

    In sorafenib-treated H9c2 cells, adding AICAR to high-dose COS increased autophagy-related protein expression compared with high-dose COS alone.

    In plain wordsIn cells, adding AICAR increased autophagy-related proteins compared with sorafenib plus high-dose COS.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseAutophagy-related protein expression
    Study

    n: not reported in source

    Sorafenib-treated H9c2 cells
    Comparator
    SOR+high-COS
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 24 hoursAs given in this study.

    Source sentences

    Summary
    Further addition of rapamycin and AICAR resulted in changes opposite to those observed in the SOR+high-COS groups(P<0.05).
    3 context sentences
    Summary · context
    H9c2 cells were divided into six groups: control(ctrl) group, SOR group, SOR + low-dose COS(SOR+low-COS) group, SOR + high-dose COS(SOR+high-COS) group, SOR + high-COS + rapamycin group, and SOR + high-COS + adenosine monophosphate-activated protein kinase(AMPK) activator(AICAR) group, with each gro…
    Summary · context
    Compared with the ctrl group, the SOR group exhibited notable changes in multiple indicators, including a significant increase in lactate dehydrogenase(LDH) leakage rate, LC3-related indices, and the expression levels of various autophagy-related proteins, as well as a significant decrease in mitoch…
    Summary · context
    Following COS administration, these indices were significantly reversed in the SOR+low-COS and SOR+high-COS groups(P<0.05).
  6. 06LabIn vitro (cells)Mechanism

    In sorafenib-treated H9c2 cells, adding AICAR to high-dose COS decreased mitochondrial membrane potential compared with high-dose COS alone.

    In plain wordsIn cells, adding AICAR lowered mitochondrial membrane potential compared with sorafenib plus high-dose COS.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseMitochondrial membrane potential
    Study

    n: not reported in source

    Sorafenib-treated H9c2 cells
    Comparator
    SOR+high-COS
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 24 hoursAs given in this study.

    Source sentences

    Summary
    Further addition of rapamycin and AICAR resulted in changes opposite to those observed in the SOR+high-COS groups(P<0.05).
    3 context sentences
    Summary · context
    H9c2 cells were divided into six groups: control(ctrl) group, SOR group, SOR + low-dose COS(SOR+low-COS) group, SOR + high-dose COS(SOR+high-COS) group, SOR + high-COS + rapamycin group, and SOR + high-COS + adenosine monophosphate-activated protein kinase(AMPK) activator(AICAR) group, with each gro…
    Summary · context
    Compared with the ctrl group, the SOR group exhibited notable changes in multiple indicators, including a significant increase in lactate dehydrogenase(LDH) leakage rate, LC3-related indices, and the expression levels of various autophagy-related proteins, as well as a significant decrease in mitoch…
    Summary · context
    Following COS administration, these indices were significantly reversed in the SOR+low-COS and SOR+high-COS groups(P<0.05).
  7. 07LabIn vitro (cells)Mechanism

    In sorafenib-treated H9c2 cells, adding AICAR to high-dose COS decreased p62 protein compared with high-dose COS alone.

    In plain wordsIn cells, adding AICAR reduced p62 protein compared with sorafenib plus high-dose COS.

    Peptide
    AICAR (acadesine)
    Outcome
    Decreasep62 protein
    Study

    n: not reported in source

    Sorafenib-treated H9c2 cells
    Comparator
    SOR+high-COS
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 24 hoursAs given in this study.

    Source sentences

    Summary
    Further addition of rapamycin and AICAR resulted in changes opposite to those observed in the SOR+high-COS groups(P<0.05).
    3 context sentences
    Summary · context
    H9c2 cells were divided into six groups: control(ctrl) group, SOR group, SOR + low-dose COS(SOR+low-COS) group, SOR + high-dose COS(SOR+high-COS) group, SOR + high-COS + rapamycin group, and SOR + high-COS + adenosine monophosphate-activated protein kinase(AMPK) activator(AICAR) group, with each gro…
    Summary · context
    Compared with the ctrl group, the SOR group exhibited notable changes in multiple indicators, including a significant increase in lactate dehydrogenase(LDH) leakage rate, LC3-related indices, and the expression levels of various autophagy-related proteins, as well as a significant decrease in mitoch…
    Summary · context
    Following COS administration, these indices were significantly reversed in the SOR+low-COS and SOR+high-COS groups(P<0.05).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.